Human Umbilical Cord Blood as a Potential Source of Transplantable Hematopoietic Stem/Progenitor Cells

The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, t...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 1989-05, Vol.86 (10), p.3828-3832
Main Authors: Broxmeyer, Hal E., Douglas, Gordon W., Hangoc, Giao, Cooper, Scott, Bard, Judith, English, Denis, Arny, Margaret, Thomas, Lewis, Boyse, Edward A.
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Blood
Blood cells
Blood Preservation
Bone marrow
Bone Marrow Cells
Bone marrow, stem cells transplantation. Graft versus host reaction
Cell Fractionation
Cells, Cultured
Colony-Forming Units Assay
Colony-Stimulating Factors - pharmacology
Cord blood
Erythrocytes
Fetal Blood - cytology
Freezing
Granulocyte macrophage progenitor cells
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Hematopoietic Stem Cells - cytology
Humans
Medical sciences
Progenitor cells
Stem cells
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Umbilical cord
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to evaluate human umbilical cord blood as an alternative to bone marrow in the provision of transplantable stem/progenitor cells for hematopoietic reconstitution. Although no direct quantitative assay for human hematopoietic repopulating cells is at present available, the granulocyte-macrophage progenitor cell (CFU-GM) assay has been used with success as a valid indicator of engrafting capability. We examined >100 collections of human umbilical cord blood for their content of nucleated cells and granulocyte-macrophage, erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells, in many cases both before and after cryopreservation. First it was determined that granulocyte-macrophage, erythroid, and multipotential progenitor cells remained functionally viable in cord blood untreated except for addition of anticoagulant for at least 3 days at 4 degrees C or 25 degrees C (room temperature), though not at 37 degrees C, implying that these cells could be satisfactorily studied and used or cryopreserved for therapy after transport of cord blood by overnight air freight carriage from a remote obstetrical service. Granulocyte-macrophage progenitor cells from cord blood so received responded normally to stimulation by purified recombinant preparations of granulocyte-macrophage, granulocyte, and macrophage colony-stimulating factors and interleukin 3. The salient finding, based on analysis of 101 cord blood collections, is that the numbers of progenitor cells present in the low-density (
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.86.10.3828